Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05688423 · ClinicalTrials.gov registry record · NA

Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients

A NA study of Substance Use Disorders and Injection Site Infection, sponsored by Columbia University.

Active
Registry status
NA
Development phase
480
Enrollment target
6
Study locations

NCT05688423 is a NA study of Substance Use Disorders and Injection Site Infection that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 480 participants, roughly in line with the 495-participant average among 93 other Substance Use Disorders trials with a reported enrollment target. The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05688423, a NA study of Substance Use Disorders and Injection Site Infection, is active but no longer recruiting, sponsored by Columbia University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
480 participants
Enrollment target
6
Study locations

Study Summary

The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whether this intervention approach will be associated with lower mortality and fewer hospital readmissions. Participants will participate in the integrated SUD/ID care team intervention (SIRI Team). Researchers will compare this intervention to treatment as usual (TUA) to see if there are any differences in health outcomes.

Conditions Studied

Substance Use Disorders Injection Site Infection

Interventions

  • BEHAVIORAL Treatment as Usual
  • BEHAVIORAL SIRI Team

Study Locations (6)

Florida

  • University of Miami - Jackson Memorial Hospital - Miami
  • Tampa General Hospital - Tampa

Alabama

  • University of Alabama at Birmingham - Birmingham

New Mexico

  • University of New Mexico Health Sciences Center - Albuquerque

Pennsylvania

  • University of Pennsylvania - Philadelphia

Utah

  • University of Utah Hospital - Salt Lake City

Trial Details

FieldValue
Enrollment Target 480 participants
Start Date 2024-01-05
Est. Completion 2027-04-03
Phase NA

Sponsor

Columbia University

958 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05688423

The ClinicalTrials.gov registry entry for NCT05688423 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 480 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 495-participant average among 93 other Substance Use Disorders trials with a reported enrollment target. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Substance Use Disorders appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.

NCT05688423 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, New Mexico.

Frequently Asked Questions

What is clinical trial NCT05688423 about?

NCT05688423 is a clinical study titled "Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients". The goal of this clinical trial is to test the effectiveness of an integrated infectious disease/substance use disorder (SUD) clinical team intervention approach in patients hospitalized with severe injection-related infections (SIRI) who use drugs. The main question this study aims to answer is whe...

What is the current status of trial NCT05688423?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 480 participants. The study started on 2024-01-05. Estimated completion is 2027-04-03.

What conditions does trial NCT05688423 study?

This clinical trial studies the following conditions: Substance Use Disorders, Injection Site Infection.

What interventions are being tested in trial NCT05688423?

The interventions under investigation include: Treatment as Usual (BEHAVIORAL), SIRI Team (BEHAVIORAL).

Who is sponsoring clinical trial NCT05688423?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05688423 being conducted?

This trial has 6 study locations across Alabama, Florida, New Mexico, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Substance Use Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Substance Use Disorders

All registered trials for this condition

Injection Site Infection

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.